Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
1.
Antibiotics (Basel) ; 12(11)2023 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-37998828

RESUMEN

The emergence of multidrug-resistant (MDR) bacteria in children is a growing concern, particularly among septic patients, given the need for first-right dosing. Our aim was to determine the incidence rates and factors associated with MDR-sepsis in the pediatric intensive care unit (PICU), using data from the Spanish ENVIN-HELICS PICU registry between 2013 and 2019. The rate of MDR bacteria among septic children ranged between 5.8 and 16.2% throughout this study period, with a significant increase since 2015 (p = 0.013). MDR-gram-negative bacteria (92%), particularly EBL-Enterobacterales (63.7%), were the most frequent causative microorganisms of MDR-sepsis. During this study period, sixteen MDR-sepsis (32.6%) corresponded to intrahospital infections, and 33 (67.4%) had community-onset sepsis, accounting for 10.5% of the overall community-onset sepsis. Independent risk factors associated with MDR-sepsis were antibiotics 48 h prior to PICU admission (OR 2.38) and PICU onset of sepsis (OR 2.58) in >1 year-old children, and previous malnourishment (OR 4.99) in <1 year-old children. Conclusions: There was an alarming increase in MDR among septic children in Spain, mainly by gram-negative (ESBL-Enterobacterales), mostly coming from the community setting. Malnourished infants and children on antibiotics 48 h prior to PICU are at increased risk and therefore require closer surveillance.

2.
J Vis Exp ; (201)2023 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-37982522

RESUMEN

Hemorrhagic shock is a leading cause of morbidity and mortality in pediatric patients. Interpretation of the clinical indicators validated in adults to guide resuscitation and comparison between different therapies is difficult in children due to the inherent heterogeneity of this population. As a result, compared to adults, appropriate management of pediatric hemorrhagic shock is still not well established. In addition, the scarcity of pediatric patients with hemorrhagic shock precludes the development of clinically relevant studies. For this reason, an experimental pediatric animal model is necessary to study the effects of hemorrhage in children as well as their response to different therapies. We present an infant animal model of volume-controlled hemorrhagic shock in anesthetized young pigs. Hemorrhage is induced by withdrawing a previously calculated blood volume, and the pig is subsequently monitored and resuscitated with different therapies. Here, we describe a precise and highly reproducible model of hemorrhagic shock in immature swine. The model yields hemodynamic data that characterizes compensatory mechanisms that are activated in response to severe hemorrhage.


Asunto(s)
Choque Hemorrágico , Adulto , Humanos , Lactante , Animales , Niño , Porcinos , Choque Hemorrágico/terapia , Volumen Sanguíneo , Modelos Animales , Resucitación
3.
An. pediatr. (2003. Ed. impr.) ; 99(1): 26-36, jul. 2023. ilus, tab
Artículo en Español | IBECS | ID: ibc-223108

RESUMEN

Introducción: No se ha establecido cuál es el aporte óptimo para mejorar el metabolismo proteico sin producir efectos adversos en lactantes gravemente enfermos. Nuestro objetivo fue analizar si un mayor aporte proteico a través de la nutrición enteral se relaciona con una mejoría en el balance proteico en lactantes críticamente enfermos. Material y métodos: Se diseñó un estudio multicéntrico, prospectivo, aleatorizado y controlado (diciembre de 2016 a junio de 2019). Se incluyeron lactantes críticamente enfermos con nutrición enteral, asignándose aleatoriamente a tres dietas con diferente contenido proteico: estándar (1,7g/100ml), hiperproteica (2,7g/100ml) e hiperproteica suplementada (5,1g/100ml). Se realizaron análisis de sangre y orina y se calculó el balance nitrogenado en el momento basal y tras 3-5días de nutrición. Se analizó la variación del balance nitrogenado y de las proteínas séricas (proteínas totales, albúmina, transferrina, prealbúmina y proteína ligada al retinol) a lo largo del periodo de estudio. Resultados: Noventa y nueve lactantes (33 por grupo) completaron el estudio. No se encontraron diferencias entre grupos en características demográficas, puntuaciones de gravedad y otros tratamientos recibidos, salvo corticoides, administrados en una mayor proporción de pacientes del tercer grupo. Tuvo lugar un aumento significativo de los niveles de prealbúmina y proteína ligada al retinol en los grupos con nutrición hiperproteica e hiperproteica suplementada. El balance nitrogenado aumentó en todos los grupos, pero este incremento no fue significativo en el grupo de nutrición hiperproteica suplementada. No se encontraron diferencias en cuanto a tolerancia gastrointestinal. Los pacientes con nutrición hiperproteica suplementada presentaron niveles superiores de urea sérica y mayor incidencia de hiperuremia. (AU)


Introduction: The optimal intake to improve protein metabolism without producing adverse effects in seriously ill infants has yet to be established. The aim of our study was to analyse whether an increased protein intake delivered through enteral nutrition would be associated with an improvement in nitrogen balance and serum protein levels in critically ill infants. Material and methods: We conducted a multicentre, prospective randomized controlled trial (December 2016-June 2019). The sample consisted of critically ill infants receiving enteral nutrition assigned randomly to 3 protein content groups: standard diet (1.7g/dL), protein-enriched diet (2.7g/dL) and high protein-enriched diet (5.1g/dL). Blood and urine tests were performed, and we assessed nitrogen balance at baseline and at 3 to 5days of the diet. We analysed variations in nitrogen balance and serum protein levels (total protein, albumin, transferrin, prealbumin, and retinol-binding protein) throughout the study period. Results: Ninety-nine infants (33 per group) completed the study. We did not find any differences were between groups in demographic characteristics, severity scores or prescribed medications, except for corticosteroids, administered in a higher proportion of patients in the third group. We observed significant increases in prealbumin and retinol-binding protein levels in patients receiving the protein-enriched and high protein-enriched diets at 3 to 5days compared to baseline. The nitrogen balance increased in all groups, but the differences were not significant in the high protein-enriched group. There were no differences in gastrointestinal tolerance. Patients fed high protein-enriched formula had higher levels of serum urea, with a higher incidence of hyperuraemia in this group. (AU)


Asunto(s)
Humanos , Masculino , Femenino , Lactante , Nutrición Enteral/efectos adversos , Proteínas/metabolismo , Estudios Prospectivos , Unidades de Cuidado Intensivo Pediátrico , Necesidades Nutricionales , Enfermedad Crítica
4.
An Pediatr (Engl Ed) ; 99(1): 26-36, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-37344303

RESUMEN

INTRODUCTION: The optimal intake to improve protein metabolism without producing adverse effects in seriously ill infants has yet to be established. The aim of our study was to analyse whether an increased protein intake delivered through enteral nutrition would be associated with an improvement in nitrogen balance and serum protein levels in critically ill infants. METHODS: We conducted a multicentre, prospective randomized controlled trial (December 2016-June 2019). The sample consisted of critically ill infants receiving enteral nutrition assigned randomly to 3 protein content groups: standard diet (1.7 g/dL), protein-enriched diet (2.7 g/dL) and high protein-enriched diet (5.1 g/dL). Blood and urine tests were performed, and we assessed nitrogen balance at baseline and at 3-5 days of the diet. We analysed variations in nitrogen balance and serum protein levels (total protein, albumin, transferrin, prealbumin, and retinol-binding protein) throughout the study period. RESULTS: Ninety-nine infants (33 per group) completed the study. We did not find any differences were between groups in demographic characteristics, severity scores or prescribed medications, except for corticosteroids, administered in a higher proportion of patients in the third group. We observed significant increases in prealbumin and retinol-binding protein levels in patients receiving the protein-enriched and high protein-enriched diets at 3-5 days compared to baseline. The nitrogen balance increased in all groups, but the differences were not significant in the high protein-enriched group. There were no differences in gastrointestinal tolerance. Patients fed high protein-enriched formula had higher levels of serum urea, with a higher incidence of hyperuraemia in this group. CONCLUSION: Enteral administration of higher amounts of protein improves serum protein levels in critically ill children. A protein intake of 2.2 g/kg/day is generally safe and well tolerated, whereas an intake of 3.4 g/kg/day may produce hyperuraemia in some patients.


Asunto(s)
Enfermedad Crítica , Prealbúmina , Niño , Humanos , Lactante , Prealbúmina/metabolismo , Enfermedad Crítica/terapia , Estudios Prospectivos , Proteínas Sanguíneas/metabolismo , Dieta , Proteínas de Unión al Retinol , Nitrógeno/metabolismo
5.
An. pediatr. (2003. Ed. impr.) ; 98(4): 276-282, abr. 2023. ilus, tab
Artículo en Español | IBECS | ID: ibc-218512

RESUMEN

Introducción: La analgosedación es una prioridad en el cuidado de pacientes en unidades de intensivos pediátricos. La combinación de ketamina y propofol puede ser una alternativa para aquellos pacientes con necesidad de sedación prolongada, con dificultad para la sedación y para disminuir el empleo de benzodiacepinas y opiáceos. El objetivo de este estudio es analizar la eficacia y seguridad de la combinación de ketamina y propofol en perfusión continua para la analgosedación en unidades de cuidados intensivos pediátricos.Materiales y métodos: Estudio de cohorte única prospectivo observacional en pacientes de 1 mes a 16 años ingresados en unidades de cuidados intensivos pediátricos entre 2016 y 2018 que recibieron tratamiento con ketamina y propofol en perfusión continua para analgosedación. Se recogieron datos clínicos y demográficos, scores de analgesia y sedación (MAPS, COMFORT-B y SOPHIA), parámetros hemodinámicos y efectos adversos. Resultados: Treinta y dos pacientes fueron incluidos. La dosis máxima de ketamina fue de 1,5mg/kg/h (RI 1-2mg/kg/h) y la duración, 5 días (RI 3-5 días). La dosis máxima de propofol fue de 3,2mg/kg/hora (RI 2,5-3,6mg/kg/hora) y la duración, 5 días (RI 3-5 días). Treinta pacientes (93,7%) habían recibido midazolam y 29 (90,6%) fentanilo previamente. Tras el inicio de la perfusión de ketamina y propofol la puntuación en la escala de analgesia no se modificó. El COMFORT-B mostró un incremento estadísticamente significativo, pero se mantuvo dentro del rango de sedación adecuada (12-17). Se produjo una leve disminución en la presión arterial media tras una hora de administración, que fue estadísticamente significativa (de 64mmHg a 60mmHg; P=0,006) así como en la presión arterial diastólica (de 50,5 a 48mmHg; P=0,023). Esta diferencia desapareció a las 12 horas del inicio y no requirió uso de drogas vasoactivas. No se detectaron efectos adversos graves durante la administración. (AU)


Introduction: Analgesia and sedation are a priority in paediatric intensive care. The combination of ketamine and propofol is a possible option in patients requiring prolonged or difficult sedation and to reduce the use of benzodiazepines and opiates. The aim of this study was to assess the efficacy and safety of combination ketamine and propofol in continuous infusion for prolonged analgesia/sedation in the paediatric intensive care setting. Patients and methods: Prospective, observational single-group cohort study in patients aged 1 month to 16 years admitted to the paediatric intensive care unit in 2016–2018 that received ketamine and propofol in continuous infusion for analgesia and sedation. We collected data on demographic and clinical characteristics, analgesia and sedation scores (MAPS, COMFORT-B and SOPHIA), haemodynamic parameters and adverse events. Results: The study included 32 patients. The maximum dose of ketamine was 1.5mg/kg/h (interquartile range [IQR], 1–2mg/kg/h) and the infusion duration was 5 days (IQR, 3–5 days). The maximum dose of propofol was 3.2mg/kg/h (IQR, 2.5–3.6mg/kg/h) and the infusion duration, 5 days (IQR, 3–5 days). Thirty (93.7%) patients had previously received midazolam and 29 (90.6%) fentanyl. Analgesia scores did not change after initiation of the ketamine and propofol infusion. There was a statistically significant increase in the COMFORT-B score, but the score remained in the adequate sedation range (12–17). There were small but statistically significant decreases in the mean arterial pressure (from 64mmHg to 60mmHg; P=.006) and the diastolic blood pressure (from 50.5 to 48mmHg; P=.023) 1h after the initiation of the ketamine and propofol infusion, but this difference was not observed 12h later and did not require administration of vasoactive drugs. No other major adverse events were detected during the infusion. (AU)


Asunto(s)
Humanos , Masculino , Femenino , Lactante , Preescolar , Niño , Adolescente , Ketamina/uso terapéutico , Propofol/uso terapéutico , Analgesia , Estudios Prospectivos , Unidades de Cuidado Intensivo Pediátrico
6.
An Pediatr (Engl Ed) ; 98(4): 276-282, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36925340

RESUMEN

INTRODUCTION: Analgesia and sedation are a priority in paediatric intensive care. The combination of ketamine and propofol is a possible option in patients requiring prolonged or difficult sedation and to reduce the use of benzodiazepines and opiates. The aim of this study was to assess the efficacy and safety of combination ketamine and propofol in continuous infusion for prolonged analgesia/sedation in the paediatric intensive care setting. PATIENTS AND METHODS: Prospective, observational single-group cohort study in patients aged 1 month to 16 years admitted to the paediatric intensive care unit in 2016-2018 that received ketamine and propofol in continuous infusion for analgesia and sedation. We collected data on demographic and clinical characteristics, analgesia and sedation scores (MAPS, COMFORT-B and SOPHIA), haemodynamic parameters and adverse events. RESULTS: The study included 32 patients. The maximum dose of ketamine was 1.5 mg/kg/h (interquartile range [IQR], 1-2 mg/kg/h) and the infusion duration was 5 days (IQR, 3-5 days). The maximum dose of propofol was 3.2 mg/kg/h (IQR, 2.5-3.6 mg/kg/h) and the infusion duration, 5 days (IQR, 3-5 days). Thirty (93.7%) patients had previously received midazolam and 29 (90.6%) fentanyl. Analgesia scores did not change after initiation of the ketamine and propofol infusion. There was a statistically significant increase in the COMFORT-B score, but the score remained in the adequate sedation range (12-17). There were small but statistically significant decreases in the mean arterial pressure (from 64 mmHg to 60 mmHg; P = .006) and the diastolic blood pressure (from 50.5 to 48 mmHg; P = .023) 1 h after the initiation of the ketamine and propofol infusion, but this difference was not observed 12 h later and did not require administration of vasoactive drugs. No other major adverse events were detected during the infusion. CONCLUSIONS: The combination of ketamine and propofol in continuous infusion is a safe treatment in critically ill children that makes it possible to achieve an appropriate level of analgesia and sedation without relevant haemodynamic repercussions.


Asunto(s)
Ketamina , Propofol , Niño , Humanos , Propofol/efectos adversos , Ketamina/efectos adversos , Hipnóticos y Sedantes/efectos adversos , Estudios Prospectivos , Estudios de Cohortes , Cuidados Críticos , Dolor
7.
Sci Rep ; 12(1): 4336, 2022 03 14.
Artículo en Inglés | MEDLINE | ID: mdl-35288599

RESUMEN

To analyze the effectiveness of dexamethasone in preventing upper airway obstruction (UAO) symptoms after extubation and the need of reintubation in critically ill children. Multicenter, prospective, double-blind, randomized, phase IV clinical trial involving five pediatric intensive care units. Children between 1 month and 16 years-of-age intubated for more than 48 h were included. Patients were randomized to receive placebo or dexamethasone 0.25 mg/kg every 6 h, 6-to-12 h prior to extubation (four doses). 48 h follow-up was carried out after extubation. Severity of UAO symptoms (Taussig score, stridor) and reintubation requirement were compared. 147 patients were randomized (10 were excluded), 70 patients received dexamethasone and 67 placebo. No global differences were found in the presence of stridor or moderate-to-severe UAO symptoms (Taussig ≥ 5), but Taussig ≥ 5 was less frequent in patients less than 2 years-of-age treated with steroids (p = 0.014). Median Taussig score was lower in the dexamethasone group 1 h after extubation, p < 0.001. 27 patients required reintubation, 9 due to UAO: 3 (4.3%) in the dexamethasone group and 6 (8.9%) in the placebo group, p = 0.319. In those intubated > 5 days, reintubation due to UAO was higher in the placebo group (2.4% vs. 14.3, p = 0.052). Nebulized epinephrine and budesonide were required more frequently in the placebo group in the first 2 h (p = 0.041) and 1 h (p = 0.02) after extubation, respectively. No relevant side effects were observed. Dexamethasone prior to extubation did not significantly reduce moderate-severe UAO symptoms, except for patients under 2-years of age. Dexamethasone could decrease Taussig score and the need of rescue therapies, as well as reintubation rates in those intubated for more than 5 days.


Asunto(s)
Obstrucción de las Vías Aéreas , Trastornos Respiratorios , Extubación Traqueal/efectos adversos , Obstrucción de las Vías Aéreas/tratamiento farmacológico , Obstrucción de las Vías Aéreas/etiología , Obstrucción de las Vías Aéreas/prevención & control , Niño , Enfermedad Crítica/terapia , Dexametasona/uso terapéutico , Humanos , Estudios Prospectivos , Trastornos Respiratorios/tratamiento farmacológico , Respiración Artificial/efectos adversos , Ruidos Respiratorios/etiología
13.
J Cardiovasc Transl Res ; 14(6): 1173-1185, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-33948868

RESUMEN

A prospective, observational single-center study was carried out. Pediatric patients undergoing congenital heart defect surgery were evaluated before, during, and after surgery. At each time point, sublingual microcirculation and clinical parameters were assessed, along with analytical variables. Twenty-four patients were included. All microcirculatory parameters worsened during cardiopulmonary bypass and returned to baseline values after surgery (p ≤ 0.001). In the intraoperative evaluation, body temperature correlated with perfused small vessel density (p = 0.014), proportion of perfused small vessels (p < 0.001), small vessel microvascular flow index (p = 0.003), and small vessel heterogeneity index (p < 0.002). Patients with cyanotic disease exhibited higher small vessel density (p < 0.008) and higher density of perfused small vessels (p < 0.022) at baseline, and a lower microvascular flow index (p = 0.022) and higher heterogeneity (p = 0.026) in the intraoperative phase. Children with congenital heart disease exhibited decreased vascular density and microvascular blood flow and increased heterogeneity during cardiopulmonary bypass. All these parameters returned to baseline values after surgery.


Asunto(s)
Cardiopatías Congénitas/cirugía , Periodo Intraoperatorio , Microcirculación , Adolescente , Velocidad del Flujo Sanguíneo , Puente Cardiopulmonar , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Estudios Prospectivos
14.
Sci Rep ; 11(1): 4631, 2021 02 25.
Artículo en Inglés | MEDLINE | ID: mdl-33633291

RESUMEN

During the last decades, the number of patients with long stay admissions (LSA) in PICU has increased. The purpose of this study was to identify factors associated with PICU LSA, assessing healthcare resources use and changes in the profile of these patients. A retrospective, observational, single-center study was carried out. Characteristics of LSA were compared between two periods (2006-2010 and 2011-2015). During the earlier period there were 2,118 admissions (3.9% of them LSA), whereas during the second period, there were 1,763 (5.4% of them LSA) (p = 0.025). LSA accounted for 33.7% PICU stay days during the first period and 46.7% during the second (p < 0.001). Higher use of non-invasive ventilation (80.2% vs. 37.8%, p = 0.001) and high-flow oxygen therapy (68.8% vs. 37.8%, p = 0.005) was observed in the 2011-2015 cohort, whereas the use of arterial catheter (77.1% vs. 92.6%, p = 0.005), continuous infusion of adrenaline (55.2% vs. 75.9%, p = 0.004), and hemoderivative transfusion (74% vs. 89.2%, p = 0.010) was less frequent. In the 2006-2010 cohort, hospital-acquired infections were more common (95.2% vs. 68.8%, p < 0.001) and mortality was higher (26.8% vs. 13.8%, p = 0.026). The number of long-stay PICU admissions have increased entailing an intensive use of healthcare resources. These patients have a high risk for complications and mortality.


Asunto(s)
Unidades de Cuidados Intensivos , Tiempo de Internación , Niño , Estudios de Cohortes , Humanos
15.
Front Pediatr ; 9: 810718, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-35155320

RESUMEN

Toxoplasma gondii infection is a severe complication of hematopoietic stem-cell transplantation (HSCT) recipients that can remain unnoticed without a high clinical suspicion. We present the case of a 6-year-old patient with acute lymphoblastic leukemia and HSCT recipient who was admitted to the Pediatric Intensive Care Unit (PICU) on post-transplantation day +39 with fever, hypotension, severe respiratory distress and appearance of a lumbar subcutaneous node. She developed severe Acute Respiratory Distress Syndrome (ARDS) and underwent endotracheal intubation and early mechanical ventilation. Subsequently, she required prone ventilation, inhaled nitric oxide therapy and high-frequency oscillatory ventilation (HFOV). An etiologic study was performed, being blood, urine, bronchoalveolar lavage and biopsy of the subcutaneous node positive for Toxoplasma gondii by Polymerase Chain Reaction (PCR). Diagnosis of disseminated toxoplasmosis was established and treatment with pyrimethamine, sulfadiazine and folinic acid started. The patient showed clinical improvement, allowing weaning of mechanical ventilation and transfer to the hospitalization ward after 40 days in the PICU. It is important to consider toxoplasmosis infection in immunocompromised patients with sepsis and, in cases of severe respiratory distress, early mechanical ventilation should be started using the open lung approach. In Toxoplasma IgG positive patients, close monitoring and appropriate anti-infectious prophylaxis is needed after HSCT.

16.
Crit Care ; 24(1): 666, 2020 11 26.
Artículo en Inglés | MEDLINE | ID: mdl-33243303

RESUMEN

BACKGROUND: Multisystem inflammatory syndrome temporally associated with COVID-19 (MIS-C) has been described as a novel and often severe presentation of SARS-CoV-2 infection in children. We aimed to describe the characteristics of children admitted to Pediatric Intensive Care Units (PICUs) presenting with MIS-C in comparison with those admitted with SARS-CoV-2 infection with other features such as COVID-19 pneumonia. METHODS: A multicentric prospective national registry including 47 PICUs was carried out. Data from children admitted with confirmed SARS-CoV-2 infection or fulfilling MIS-C criteria (with or without SARS-CoV-2 PCR confirmation) were collected. Clinical, laboratory and therapeutic features between MIS-C and non-MIS-C patients were compared. RESULTS: Seventy-four children were recruited. Sixty-one percent met MIS-C definition. MIS-C patients were older than non-MIS-C patients (p = 0.002): 9.4 years (IQR 5.5-11.8) vs 3.4 years (IQR 0.4-9.4). A higher proportion of them had no previous medical history of interest (88.2% vs 51.7%, p = 0.005). Non-MIS-C patients presented more frequently with respiratory distress (60.7% vs 13.3%, p < 0.001). MIS-C patients showed higher prevalence of fever (95.6% vs 64.3%, p < 0.001), diarrhea (66.7% vs 11.5%, p < 0.001), vomits (71.1% vs 23.1%, p = 0.001), fatigue (65.9% vs 36%, p = 0.016), shock (84.4% vs 13.8%, p < 0.001) and cardiac dysfunction (53.3% vs 10.3%, p = 0.001). MIS-C group had a lower lymphocyte count (p < 0.001) and LDH (p = 0.001) but higher neutrophil count (p = 0.045), neutrophil/lymphocyte ratio (p < 0.001), C-reactive protein (p < 0.001) and procalcitonin (p < 0.001). Patients in the MIS-C group were less likely to receive invasive ventilation (13.3% vs 41.4%, p = 0.005) but were more often treated with vasoactive drugs (66.7% vs 24.1%, p < 0.001), corticosteroids (80% vs 44.8%, p = 0.003) and immunoglobulins (51.1% vs 6.9%, p < 0.001). Most patients were discharged from PICU by the end of data collection with a median length of stay of 5 days (IQR 2.5-8 days) in the MIS-C group. Three patients died, none of them belonged to the MIS-C group. CONCLUSIONS: MIS-C seems to be the most frequent presentation among critically ill children with SARS-CoV-2 infection. MIS-C patients are older and usually healthy. They show a higher prevalence of gastrointestinal symptoms and shock and are more likely to receive vasoactive drugs and immunomodulators and less likely to need mechanical ventilation than non-MIS-C patients.


Asunto(s)
COVID-19/epidemiología , Neumonía Viral/epidemiología , Síndrome de Respuesta Inflamatoria Sistémica/epidemiología , Adolescente , Niño , Preescolar , Femenino , Humanos , Unidades de Cuidado Intensivo Pediátrico , Masculino , Pandemias , Estudios Prospectivos , Sistema de Registros , SARS-CoV-2 , España/epidemiología
18.
An. pediatr. (2003. Ed. impr.) ; 92(4): 208-214, abr. 2020. tab
Artículo en Español | IBECS | ID: ibc-196212

RESUMEN

INTRODUCCIÓN: El objetivo de este estudio ha sido analizar el estado de nutrición, la alimentación y las complicaciones digestivas de los niños que precisan técnicas de depuración extrarrenal continua (TDEC). MATERIAL Y MÉTODOS: Estudio retrospectivo realizado sobre una base de datos prospectiva de los niños tratados con TDEC entre 2013 y 2017. Se analizaron las características de los pacientes, la técnica de depuración, el tipo de nutrición, el aporte calórico y proteico, las complicaciones digestivas y la evolución clínica. RESULTADOS: Sesenta y cinco niños (61,5% varones) fueron tratados con TDEC y 24 (37%) precisaron soporte con oxigenación con membrana extracorpórea. Un 27,7% tenían un peso inferior al percentil 3 y un 48,4% una talla inferior al percentil 3. Al inicio de la TDEC 31 niños (47,7%) recibían nutrición enteral y 52 (80%) al final de la misma. La nutrición enteral fue por sonda transpilórica en el 76% de los casos. La mediana de aporte calórico fue de 63 kcal/kg/día y la del aporte proteico de 1,6 g/kg/día. Cuarenta y ocho pacientes (73,8%) presentaron complicaciones digestivas: 29 (44,6%) distensión gástrica o restos gástricos excesivos, 22 (33,8%) estreñimiento, 8 (12,3%) vómitos y 4 (6,1%) diarrea. Un paciente con oxigenación con membrana extracorpórea presentó isquemia intestinal. En 3 pacientes (4,6%) se tuvo que suspender la nutrición enteral por complicaciones. No existió relación entre las complicaciones y el tipo de alimentación o la asistencia en oxigenación con membrana extracorpórea. CONCLUSIONES: Un elevado porcentaje de niños tratados con TDEC presentan malnutrición, pero la mayoría pueden ser alimentados con nutrición enteral. Aunque el porcentaje de complicaciones digestivas es elevado, en pocos pacientes se tiene que suspender la nutrición enteral


INTRODUCTION: The aim of this study was to analyse the nutritional state, diet and gastrointestinal complications of children that require continuous renal replacement therapy (CRRT). MATERIAL AND METHODS: A retrospective analysis of a database, which included the information about patients who required CRRT between the years 2013 and 2017. Data were collected on the replacement technique, type of nutrition, calorie and protein intake, gastrointestinal complications, and clinical course. RESULTS: A total of 65 children (61.5% male) were treated with CRRT, and 24 patients (37%) also needed ECMO support. Just over one-quarter (27.7%) of patients had a weight less than P3, and 48.4% of them a height less than P3. At the beginning of the technique, 31 children (47.7%) received enteral nutrition, at the end, there were 52 patients receiving enteral nutrition (80%). The transpyloric tube was used to provide nutrition in 76% of the cases. The median caloric intake was 63kcal/kg/day, and the protein intake was 1.6g/kg/day. There were gastrointestinal difficulties during the process in 48 patients (73.8%), with 29 (44.6%) patients being diagnosed with gastric distension or excessive gastric remains, 22 (33.8%) with constipation, 8 (12.3%) with vomiting, and 4 (6.1%) diarrhoea. One patient treated with ECMO presented with intestinal ischaemia. Enteral nutrition was cancelled in 3 patients (4.6%) due to the complications. There was no relationship between complications and type of diet or ECMO assistance. CONCLUSIONS: A high percentage of children treated with CRRT showed undernutrition but they had adequate tolerance to the enteral nutrition. Although the gastrointestinal complications percentage was high in few subjects, these complications are the reason why enteral nutrition was stopped


Asunto(s)
Humanos , Masculino , Femenino , Lactante , Preescolar , Niño , Enfermedades del Sistema Digestivo/etiología , Nutrición Parenteral , Nutrición Enteral , Hemodiafiltración , Fluidoterapia , Análisis de Supervivencia , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...